With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of Eli Lilly’s Foundayo in 2026, as well as the dynamics at play with Novo ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results